NasdaqGM - Delayed Quote • USD
Coherus BioSciences, Inc. (CHRS)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:47 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 4 | 5 |
| Avg. Estimate | -0.24 | -0.22 | -0.78 | 0.04 |
| Low Estimate | -0.37 | -0.33 | -0.96 | -0.57 |
| High Estimate | -0.05 | -0.04 | -0.41 | 0.68 |
| Year Ago EPS | -0.75 | -0.38 | -1.98 | -0.78 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 7 | 7 |
| Avg. Estimate | 81.7M | 53.68M | 261.64M | 357.26M |
| Low Estimate | 47.07M | 49.56M | 206.49M | 279.91M |
| High Estimate | 102M | 68M | 324M | 513.75M |
| Year Ago Sales | 47.44M | -- | 257.24M | 261.64M |
| Sales Growth (year/est) | 72.20% | -- | 1.70% | 36.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.57 | -0.48 | -0.27 | -0.12 |
| EPS Actual | -0.75 | -0.38 | -0.27 | -0.62 |
| Difference | -0.18 | 0.1 | 0 | -0.5 |
| Surprise % | -31.60% | 20.80% | 0.00% | -416.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.24 | -0.22 | -0.78 | 0.04 |
| 7 Days Ago | -0.19 | -0.19 | -0.58 | 0.07 |
| 30 Days Ago | -0.23 | -0.22 | -0.87 | -0.07 |
| 60 Days Ago | -0.23 | -0.18 | -0.25 | 0.01 |
| 90 Days Ago | -0.2 | -0.12 | -0.12 | 0.35 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CHRS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 68.00% | -- | -- | 1.60% |
| Next Qtr. | 42.10% | -- | -- | 10.50% |
| Current Year | 60.60% | -- | -- | 5.20% |
| Next Year | 105.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -25.10% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
| Maintains | Baird: Outperform to Outperform | 1/23/2024 |
| Maintains | Truist Securities: Buy to Buy | 1/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/27/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/7/2023 |
Related Tickers
KPTI Karyopharm Therapeutics Inc.
1.1700
-8.59%
TSVT 2seventy bio, Inc.
4.5200
-2.59%
OMGA Omega Therapeutics, Inc.
2.4000
-0.83%
FGEN FibroGen, Inc.
1.1500
-1.71%
ATRA Atara Biotherapeutics, Inc.
0.6610
-4.44%
CKPT Checkpoint Therapeutics, Inc.
1.4600
-8.75%
ACET Adicet Bio, Inc.
1.9500
-3.70%
ADCT ADC Therapeutics SA
4.7200
-0.84%
CTMX CytomX Therapeutics, Inc.
1.6700
-3.47%
AGEN Agenus Inc.
5.31
+6.84%